Among the commonly used chemotherapeutic agents in CRC patients, topoisomerase 1 (TOP1) inhibitors have been shown to promote the maturation of dendritic cells, thereby contributing to antitumor immunity through a STING-dependent pathway [11, 38, 39]. This evidence concerns the gene STING1 and colorectal carcinoma.